Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock
Healthcare · Biotechnology · US
$0.12
-17.13%
Last updated Aug 3, 2026 04:31 UTC
LIMN Key Statistics
Market Cap$3.28M
P/E (TTM)-0.04
P/S (TTM)—
P/B (TTM)-0.30
Revenue (TTM)$0.00
EPS (TTM)$-2.91
Dividend Yield—
ROE (TTM)194.96%
Net Margin0.00%
Gross Margin0.00%
52W High$0.36
52W Low$0.10
Analyst View—
Price Target—
Employees3
Volume10,598,341
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
CEO: Chris Kim. Company website
See LIMN live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open LIMN in Terminal See plans